Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Motif Bio PLC    MTFB   GB00BVVT4H71

MOTIF BIO PLC

(MTFB)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
03/13/2019 03/14/2019 03/15/2019 03/18/2019 03/19/2019 Date
6.1(c) 5.8(c) 5.7(c) 5.86(c) 5.9(c) Last
2 617 166 5 321 217 5 898 258 4 264 095 3 263 547 Volume
-5.43% -4.92% -1.72% +2.81% +0.68% Change
More quotes
Financials (GBP)
Sales 2018 -
EBIT 2018 -20,8 M
Net income 2018 -
Finance 2018 2,26 M
Yield 2018 -
Sales 2019 20,5 M
EBIT 2019 -1,96 M
Net income 2019 -
Finance 2019 0,86 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 0,81x
Capitalization 17,6 M
More Financials
Company
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The... 
More about the company
Latest news on MOTIF BIO PLC
03/18MOTIF BIO : Announces Appointment of Bruce Williams as Interim Chairman and Resi..
PU
03/18Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Res..
GL
02/19HERCULES CAPITAL : Motif BioSciences Enters into Amendment Agreement with Hercul..
AQ
02/19Motif Bio Conference Call and Webcast
GL
02/19MOTIF BIO : reaches deal to reduce repayment burden
AQ
02/18Motif BioSciences Enters into Amendment Agreement with Hercules Capital
GL
02/14Motif Bio Receives Complete Response Letter from the FDA
GL
02/06MOTIF BIO : Exercise of Warrants
AQ
01/24MOTIF BIO : Exercise of Warrants
AQ
2018Motif Bio to participate at upcoming Jefferies London Healthcare Conference
GL
More news
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart MOTIF BIO PLC
Duration : Period :
Motif Bio PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOTIF BIO PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 1,08  GBP
Spread / Average Target 1 731%
EPS Revisions
Managers
NameTitle
Graham George Lumsden Chief Executive Officer & Executive Director
Richard Cecil Eversfield Morgan Non-Executive Chairman
Jonathan E. Gold Chief Financial Officer & Executive Director
David B. Huang Chief Medical Officer
Rajesh B. Shukla Vice President-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MOTIF BIO PLC-81.18%23
GILEAD SCIENCES4.70%82 934
VERTEX PHARMACEUTICALS13.15%47 931
REGENERON PHARMACEUTICALS8.97%43 762
GENMAB4.54%10 443
SAREPTA THERAPEUTICS INC15.89%9 344